Which hedge funds own RARE? ULTRAGENYX PHARMACEUTICAL IN, Q2 2026 13F holders
Healthcare · Open on the interactive board
9 of the hedge funds tracked by WhaleCreep disclosed a position in RARE (ULTRAGENYX PHARMACEUTICAL IN) in their Q2 2026 13F filings, worth $228.3m in total. The largest holder by portfolio weight is Sands Capital Management at 0.4% of its book. 2 exited: Point72 Asset Management LP, Tudor Investment.
9tracked managers holding
0opened this quarter
2exited this quarter
Which hedge funds hold RARE? Current holders by portfolio weight
| Manager | As of | Weight of book | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|
| Sands Capital Management | Q2 2026 | 0.4% | $105.5m | 3,158,368 | -2% | reduced |
| Moore Capital Management | Q2 2026 | 0.1% | $4.3m | 128,035 | -19% | reduced |
| Brevan Howard Capital Management | Q2 2026 | 0.0% | $3.4m | 102,768 | -52% | reduced |
| D. E. Shaw & Co | Q2 2026 | 0.0% | $57.8m | 1,730,193 | 37% | added |
| Renaissance Technologies LLC | Q2 2026 | 0.0% | $13.8m | 413,700 | -26% | reduced |
| Woodline Partners | Q2 2026 | 0.0% | $5.7m | 171,805 | 0% | held |
| Millennium Management | Q2 2026 | 0.0% | $25.4m | 760,825 | -57% | reduced |
| Marshall Wace | Q2 2026 | 0.0% | $5.3m | 159,889 | 2% | added |
| Citadel Advisors | Q2 2026 | 0.0% | $7.0m | 210,531 | -90% | reduced |
Exited since the previous quarter
| Manager | Prior weight | Prior value |
|---|---|---|
| Point72 Asset Management LP | 0.4% | $18.7m |
| Tudor Investment | 0.1% | $1.1m |
How has hedge fund ownership of RARE changed?
| Quarter | Managers holding | Combined value |
|---|---|---|
| Q2 2026 | 9 | $228.3m |
| Q1 2026 | 11 | $221.5m |
| Q4 2025 | 7 | $147.6m |
| Q3 2025 | 8 | $201.9m |
| Q2 2025 | 11 | $341.4m |
| Q1 2025 | 11 | $332.3m |
| Q4 2024 | 10 | $359.2m |
| Q3 2024 | 12 | $535.8m |
| Q2 2024 | 10 | $430.1m |
| Q1 2024 | 9 | $378.9m |
| Q4 2023 | 9 | $414.0m |
| Q3 2023 | 9 | $247.3m |
| Q2 2023 | 11 | $262.6m |
| Q1 2023 | 9 | $297.4m |
| Q4 2022 | 6 | $359.3m |
| Q3 2022 | 7 | $136.3m |
Counts every tracked manager that disclosed RARE in that quarter's filing, including managers that have since stopped filing.